Verily, which is a subsidiary of Google’s parent company Alphabet, yesterday announced that it had partnered with Novartis, Otsuka, Pfizer, and Sanofi in efforts to develop digitally-innovative clinical research programmes.
US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
The US Court of Appeals for the Federal Circuit yesterday, May 8, rejected an appeal from Amgen in patent litigation relating to two Sandoz biosimilars.
Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.
A former scientist at Bayer CropScience shared confidential information with his new employer, which was used to develop commercial biopesticide products, according to a claim filed by the agricultural company.
A judge has dismissed actor Clint Eastwood’s motion to gain ownership over two diabetes patents currently assigned to Molecular Defenses Corporation.
Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.
A division of Novartis has entered into an agreement with Taiwan-based EirGenix to market a medicine which treats some cancer tumours.